Cryolife Inc (CRY) Receives $23.63 Consensus PT from Brokerages

Shares of Cryolife Inc (NYSE:CRY) have earned an average rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $23.63.

Several equities analysts have commented on CRY shares. Canaccord Genuity reissued a “buy” rating and set a $25.00 price objective on shares of Cryolife in a research report on Monday, October 9th. Zacks Investment Research raised Cryolife from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Northland Securities reaffirmed a “buy” rating and issued a $23.50 price target on shares of Cryolife in a research report on Monday, November 13th. TheStreet lowered Cryolife from a “b” rating to a “c+” rating in a research report on Monday, October 30th. Finally, Lake Street Capital lifted their price target on Cryolife to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, October 11th.

In other news, CAO Amy Horton sold 4,000 shares of Cryolife stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total value of $76,000.00. Following the completion of the transaction, the chief accounting officer now owns 98,705 shares of the company’s stock, valued at approximately $1,875,395. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP David C. Gale sold 20,000 shares of Cryolife stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $19.63, for a total value of $392,600.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 59,190 shares of company stock valued at $1,138,240. 6.00% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of CRY. Russell Investments Group Ltd. purchased a new position in shares of Cryolife in the 3rd quarter worth about $6,164,000. Macquarie Group Ltd. raised its position in Cryolife by 16.0% in the 3rd quarter. Macquarie Group Ltd. now owns 1,609,284 shares of the medical equipment provider’s stock worth $36,531,000 after buying an additional 221,574 shares during the last quarter. Thomson Horstmann & Bryant Inc. raised its position in Cryolife by 139.0% in the 3rd quarter. Thomson Horstmann & Bryant Inc. now owns 224,518 shares of the medical equipment provider’s stock worth $5,096,000 after buying an additional 130,593 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Cryolife by 6.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,960,221 shares of the medical equipment provider’s stock worth $39,107,000 after buying an additional 110,973 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Cryolife by 6.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,658,646 shares of the medical equipment provider’s stock worth $33,090,000 after buying an additional 102,540 shares during the last quarter. 73.63% of the stock is owned by hedge funds and other institutional investors.

Shares of Cryolife (NYSE:CRY) traded up $0.10 during trading on Friday, reaching $18.45. The company’s stock had a trading volume of 86,991 shares, compared to its average volume of 109,000. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90. The stock has a market capitalization of $613.95, a price-to-earnings ratio of 65.89 and a beta of 0.82. Cryolife has a fifty-two week low of $14.02 and a fifty-two week high of $24.00.

Cryolife (NYSE:CRY) last announced its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 EPS for the quarter, meeting the consensus estimate of $0.08. The business had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. Cryolife had a return on equity of 6.43% and a net margin of 5.28%. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.13 earnings per share. equities analysts expect that Cryolife will post 0.28 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2018/01/22/cryolife-inc-cry-receives-23-63-consensus-pt-from-brokerages.html.

About Cryolife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit